# INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

> **NCT05151640** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 158 (actual)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT05151640
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-08
- **Primary completion:** 2025-09-05
- **Final completion:** 2025-09-05
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05151640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05151640, "INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05151640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*